Director, Clinical-Translational Science
Brisbane, QLD, Australia · Full-time
Series D · $315M · 130d ago Posted 2mo ago
This role was taken down by AdvanCell 3d ago. It may have been filled.
Why join AdvanCell?
Radiation that reaches only the tumor becomes the default cancer treatment, and older therapies start to look dated. AdvanCell, a Sydney radiopharmaceutical developer, is building that with targeted alpha therapies, and owning both development and manufacturing could make it a supplier drug makers rely on. Eli Lilly and Bain Capital Life Sciences sit among the leads on a $315M Series D, bringing its total to $453M across 5 rounds.
JustBacked's take, based on AdvanCell's own site and its funding and hiring data.
The Director, Clinical-Translational Science will provide scientific leadership across AdvanCell’s biobanking and clinical translational research activities, supporting the delivery of translational research aligned with clinical development objectives.
The role will provide scientific oversight and technical support for sample processing, storage, data management and analysis, ensuring all activities are conducted to the appropriate quality, safety and regulatory standards. The role will lead and coordinate translational research initiatives using clinical samples and data to identify and develop novel biomarkers and research, working collaboratively with AdvanCell’s cross-functional teams and external partners.
It will also support the development and expansion of in-house research capabilities, scientific interpretation and communication, and the translation of research findings into insights that inform clinical development and research decision-making.